NEW YORK (GenomeWeb) – Myriad Genetics presented new data this week on the impact of its GeneSight pharmacogenomic test in the care of patients with moderate to severe depression, and expressed confidence that the data, alongside other clinical impact and health economic evidence, will help it broaden payor coverage for the test.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.